Equity Capital Markets

Alnylam Pharmaceuticals, Inc.

11/17
|
$805.0 Million
Piper Sandler served as co-manager for Alnylam Pharmaceuticals, Inc on a follow-on offering
Sub-Type
Follow-On Offering
Sector
Healthcare
Sub-Sector
Biopharma

Related Transactions

All Transactions
$75.0 Million
w
Protara Therapeutics
Confidentially Marketed Follow-On Offering
Active Bookrunner
$172.5 Million
e
Capricor Therapeutics
Confidentially Marketed Follow-On Offering
Left Bookrunner
$158.7 Million
s
Kestra Medical Technologies
Follow-On Offering
Active Bookrunner
$40.2 Million
s
Fennec Pharmaceuticals
Confidentially Marketed Follow-On Offering
Lead Bookrunner
g
MultiPlan, Inc.
Confidentially Marketed Follow-On Offering
Passive Bookrunner
$110.0 Million
3
Nektar Therapeutics
ATM Program Common Stock
Lead Sales Agent
$172.5 Million
p
Inventiva Pharma
Confidentially Marketed Follow-On Offering
Active Bookrunner
$28.8 Million
e
Inovio Pharmaceuticals
Confidentially Marketed Follow-On Offering
Sole Manager
$314.0 Million
f
BillionToOne
Initial Public Offering
Active Bookrunner
$1.5 Billion
e
3
OrganOx
OrganOx has been acquired by Terumo
Financial Advisor
$130.0 Million
h
Savara
Confidentially Marketed Follow-On Offering
Active Bookrunner
$603.8 Million
r
Praxis Precision Medicines
Confidentially Marketed Follow-On Offering
Active Bookrunner
$50.0 Million
s
Adagio Medical Inc.
PIPE
Sole Placement Agent
$100.0 Million
Inventiva
Inventiva
ATM Program Common Stock
Sole Sales Agent
$75.0 Million
r
Esperion Therapeutics
Confidentially Marketed Follow-On Offering
Lead Bookrunner
d
e
Phoenix Physical Therapy
Sr. Secured Term Loan
Delayed Draw Term Loan & Revolver
Sole Placement Agent

© 2025 Piper Sandler Companies. Since 1895. All rights reserved.